TFF Pharmaceuticals, Inc. (TFFP)
| Previous close | 3.0900 |
| Open | 3.1651 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.8000 - 3.1651 |
| 52-week range | 2.5100 - 21.2500 |
| Volume | |
| Avg. volume | 31,987 |
| Market cap | 7.558M |
| Beta (5Y monthly) | 1.29 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -11.8500 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 24.50 |
GlobeNewswireTFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
New Gene Expression Analysis from Ongoing Phase 2 Study Provides Strong Biomarker Evidence that Treatment with TFF TAC Results in Normalization of Rejection-Related Genes TFF TAC Prevented Rejection at 1/6 of Oral Tacrolimus Dose and with 2/3 of Oral Tacrolimus Systemic Trough Exposures 4 out of 4 Patients Who Completed the 12-Week Treatment Have Chosen to Remain on TFF TAC by Proceeding to the Safety Extension Phase FORT WORTH, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc.
Simply Wall St.TFF Pharmaceuticals Full Year 2023 Earnings: Misses Expectations
TFF Pharmaceuticals ( NASDAQ:TFFP ) Full Year 2023 Results Key Financial Results Net loss: US$21.2m (loss narrowed by...
- GlobeNewswire
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
FORT WORTH, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the fourth quarter and full year 2023. “Over the last several months, we have made significant progress showing that our Thin Film Freezing technology can be successfully ap
